Список литературы

1. Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, Piltonen T, Norman RJ; International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018 Aug; 110(3): 364 - 379.

2. Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E; American Association of Clinical Endocrinologists (AACE); American College of Endocrinology (ACE); Androgen Excess and PCOS Society. American Association of Clinical Endocrinologists, American College Of Endocrinology, And Androgen Excess and Pcos Society Disease State Clinical Review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome - part 2. Endocr Pract. 2015 Dec; 21(12): 1415 - 26.

3. Randeva HS, Tan BK, Weickert MO, Lois K, Nestler JE, Sattar N, Lehnert H. Cardiometabolic aspects of the polycystic ovary syndrome. Endocr Rev. 2012 Oct; 33(5): 812 - 41.

4. Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, et al. Polycysticovarysyndrome. NatureReviewsDiseasePrimers 2016; 2: 16057.

5. Neven ACH, Laven J, Teede HJ, Boyle JA. A Summary on Polycystic Ovary Syndrome: Diagnostic Criteria, Prevalence, Clinical Manifestations, and Management According to the Latest International Guidelines. Semin Reprod Med. 2018; 36(1): 5 - 12.

6. Carmina E, Guastella E, Longo RA. Advances in the Diagnosis and Treatment of PCOS. Curr Pharm Des. 2016; 22(36): 5508 - 5514.

7. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004; 19(1): 41 - 7.

8. Spritzer PM, Barone CR, Oliveira FB. Hirsutism in Polycystic Ovary Syndrome: Pathophysiology and Management. Curr Pharm Des. 2016; 22(36): 5603 - 5613.

9. Ezeh U, Huang A, Landay M, Azziz R. Long-Term Response of Hirsutism and Other Hyperandrogenic Symptoms to Combination Therapy in Polycystic Ovary Syndrome. J Womens Health (Larchmt). 2018 Jul; 27(7): 892 - 902.

10. Lizneva D, Gavrilova-Jordan L, Walker W, Azziz R. Androgen excess: Investigations and management. Best Pract Res Clin Obstet Gynaecol. 2016 Nov; 37: 98 - 118.

11. Escobar-Morreale HF, Carmina E, Dewailly D et al. Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update. 2012 Mar - Apr; 18(2): 146 - 70.

12. Legro RS, Schlaff WD, Diamond MP et al. Total testosterone assays in women with polycystic ovary syndrome: precision and correlation with hirsutism. J Clin Endocrinol Metab. 2010 Dec; 95(12): 5305 - 13.

13. Lause M, Kamboj A, Fernandez Faith E. Dermatologic manifestations of endocrine disorders. Transl Pediatr. 2017 Oct; 6(4): 300 - 312.

14. Melibary YT. Hidradenitis suppurativa in a patient with hyperandrogenism, insulin-resistance and acanthosis nigricans (HAIR-AN syndrome). Dermatol Reports. 2018; 10(1): 7546.

15. Keen MA, Shah IH, Sheikh G. Cutaneous Manifestations of Polycystic Ovary Syndrome: A Cross-Sectional Clinical Study. Indian Dermatol Online J. 2017; 8(2): 104 - 110.

16. Rodgers R, Avery J, Moore V, Davies M, Azziz R, Stener-Victorin E, Moran L, Robertson S, Stepto N, Norman R, Teede HJ. Complex diseases and co-morbidities: polycystic ovary syndrome and type 2 diabetes mellitus. Endocr Connect. 2019 Feb 1. pii: EC-18-0502. R2.

17. Legro RS. Obesity and PCOS: implications for diagnosis and treatment. Semin Reprod Med. 2012 Dec; 30(6): 496 - 506.

18. Glueck CJ, Goldenberg N. Characteristics of obesity in polycystic ovary syndrome: Etiology, treatment, and genetics. Metabolism. 2019; 92: 108 - 120.

19. Pasquali R, Oriolo C. Obesity and Androgens in Women. Front Horm Res. 2019; 53: 120 - 134.

20. Zheng SH, Li XL. Visceral adiposity index as a predictor of clinical severity and therapeutic outcome of PCOS. Gynecol Endocrinol. 2016; 32(3): 177 - 83.

21. Gibson-Helm M, Teede H, Dunaif A, Dokras A, et al. Delayed diagnosis and a lack of information associated with dissatisfaction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2017; 102(2): 604 - 12

22. Dokras A, Saini S, Gibson-Helm M, Schulkin J, Cooney L, Teede H. Gaps in knowledge among physicians regarding diagnostic criteria and management of polycystic ovary syndrome. Fertil Steril 2017; 107(6): 1380 - 6.e1.

23. Balen AH, Morley LC, Misso M, Franks S, Legro RS, Wijeyaratne CN, et al. The management of anovulatory infertility in women with polycystic ovary syndrome: An analysis of the evidence to support the development of global WHO guidance. Hum Reprod Update 2016; 22(6): 687 - 708.

24. Wild RA, Carmina E, Diamanti-Kandarakis E et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab. 2010 May; 95(5): 2038 - 49.

25. Andersen M, Glintborg D. Diagnosis and follow-up of type 2 diabetes in women with PCOS: a role for OGTT? Eur J Endocrinol. 2018 Sep; 179(3): D1 - D14. doi: 10.1530/EJE-18-0237.

26. Anagnostis P, Tarlatzis BC, Kauffman RP. Polycystic ovarian syndrome (PCOS): Long-term metabolic consequences. Metabolism. 2018; 86: 33 - 43.

27. Nolan CJ, Prentki M. Insulin resistance and insulin hypersecretion in the metabolic syndrome and type 2 diabetes: Time for a conceptual framework shift. Diab Vasc Dis Res. 2019 Mar; 16(2): 118 - 127.

28. Pelanis R, Mellembakken JR, 00000002.wmz I, et al. The prevalence of Type 2 diabetes is not increased in normal-weight women with PCOS. Hum Reprod. 2017; 32(11): 2279 - 2286.

29. Condorelli RA, Calogero AE, Di Mauro M, La Vignera S. PCOS and diabetes mellitus: from insulin resistance to altered beta pancreatic function, a link in evolution. Gynecol Endocrinol. 2017 Sep; 33(9): 665 - 667.

30. Jeanes YM, Reeves S. Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges. Nutr Res Rev. 2017 Jun; 30(1): 97 - 105.

31. Bani Mohammad M, Majdi Seghinsara A. Polycystic Ovary Syndrome (PCOS), Diagnostic Criteria, and AMH. Asian Pac J Cancer Prev. 2017 Jan 1; 18(1): 17 - 21.

32. Teede H, Misso M, Tassone EC, Dewailly D, Ng EH, Azziz R, Norman RJ, Andersen M, Franks S, Hoeger K, Hutchison S, Oberfield S, Shah D, Hohmann F, Ottey S, Dabadghao P, Laven JSE. 00000003.wmz Hormone in PCOS: A Review Informing International Guidelines. Trends Endocrinol Metab. 2019 Jul; 30(7): 467 - 478.

33. Garg D, Tal R. The role of AMH in the pathophysiology of polycystic ovarian syndrome. Reprod Biomed Online. 2016 Jul; 33(1): 15 - 28.

34. Sova H, Unkila-Kallio L, Tiitinen A, 00000004.wmz M, Perheentupa A, Tinkanen H, Puukka K, Bloigu R, Piltonen T, Tapanainen JS, Morin-Papunen L. Hormone profiling, including 00000005.wmz hormone (AMH), for the diagnosis of polycystic ovary syndrome (PCOS) and characterization of PCOS phenotypes. Gynecol Endocrinol. 2019; 35(7): 595 - 600.

35. Yildiz BO, Bozdag G, Yapici Z, Esinler I, Yarali H. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod. 2012; 27: 3067 - 73.

36. Alberti KG, Eckel RH, Grundy SM et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009 Oct 20; 120(16): 1640 - 5.

37. Kakoly NS, Khomami MB, Joham AE, Cooray SD, Misso ML, Norman RJ, Harrison CL, Ranasinha S, Teede HJ, Moran LJ. Ethnicity, obesity and the prevalence of impaired glucose tolerance and type 2 diabetes in PCOS: a systematic review and meta-regression. Hum Reprod Update. 2018 Jul 1; 24(4): 455 - 467.

38. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, Welt CK. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013 Dec; 98(12): 4565 - 92.

39. Rosenfield RL. The Polycystic Ovary Morphology-Polycystic Ovary Syndrome Spectrum. J Pediatr Adolesc Gynecol. 2015 Dec; 28(6): 412 - 9.

40. Dewailly D, Lujan ME, Carmina E, Cedars MI, Laven J, Norman RJ, Escobar-Morreale HF. Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update. 2014 May - Jun; 20(3): 334 - 52.

41. Zhu RY, Wong YC, Yong EL. Sonographic evaluation of polycystic ovaries. Best Pract Res Clin Obstet Gynaecol. 2016 Nov; 37: 25 - 37.

42. Федеральные клинические рекомендации Болезнь Иценко-Кушинга, 2016

43. Федеральные клинические рекомендации Врожденная дисфункция коры надпочечников у взрослых, 2016

44. Федеральные клинические рекомендации Гиперпролактинемия, 2016

45. Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C, Grobman WA, Laurberg P, Lazarus JH, Mandel SJ, Peeters RP, Sullivan S. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid. 2017 Mar; 27(3): 315 - 389.

46. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009; 91: 456 - 88.

47. Osibogun O, Ogunmoroti O, Michos ED. Polycystic ovary syndrome and cardiometabolic risk: Opportunities for cardiovascular disease prevention. Trends Cardiovasc Med. 2020 Oct; 30(7): 399 - 404.

48. Wild RA. Dyslipidemia in PCOS. Steroids. 2012 Mar 10; 77(4): 295 - 9.

49. Papadakis G, Kandaraki E, Papalou O, Vryonidou A, Diamanti-Kandarakis E. Is cardiovascular risk in women with PCOS a real risk? Current insights. Minerva Endocrinol. 2017 Dec; 42(4): 340 - 355.

50. Meun C, Gunning MN, Louwers YV, Peters H, Roos-Hesselink J, Roeters van Lennep J, Rueda Ochoa OL, Appelman Y, Lambalk N, Boersma E, Kavousi M, Fauser BC, Laven JS; CREW consortium. The cardiovascular risk profile of middle-aged women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2020 Feb; 92(2): 150 - 158.

51. Delitala AP, Capobianco G, Delitala G, Cherchi PL, Dessole S. Polycystic ovary syndrome, adipose tissue and metabolic syndrome. Arch Gynecol Obstet. 2017 Sep; 296(3): 405 - 419.

52. Damone AL, Joham AE, Loxton D, Earnest A, Teede HJ, Moran LJ. Depression, anxiety and perceived stress in women with and without PCOS: a community-based study. Psychol Med. 2019 Jul; 49(9): 1510 - 1520.

53. Cooney LG, Dokras A. Depression and Anxiety in Polycystic Ovary Syndrome: Etiology and Treatment. Curr Psychiatry Rep. 2017 Sep 20; 19(11): 83.

54. Rodriguez-Paris D, Remlinger-Molenda A, Kurzawa R, 00000006.wmz A, 00000007.wmz R, Rybakowski F, 00000008.wmz L, Banaszewska B. Psychiatric disorders in women with polycystic ovary syndrome. Psychiatr Pol. 2019 Aug 31; 53(4): 955 - 966.

55. Brutocao C, Zaiem F, Alsawas M, Morrow AS, Murad MH, Javed A. Psychiatric disorders in women with polycystic ovary syndrome: a systematic review and meta-analysis. Endocrine. 2018 Nov; 62(2): 318 - 325.

56. Lim SS, Hutchison SK, Van Ryswyk E, Norman RJ, Teede HJ, Moran LJ. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev 2019; 3: CD007506.

57. Oberg E, Gidlof S, Jakson I, Mitsell M, Tollet Egnell P, Hirschberg AL. Improved menstrual function in obese women with polycystic ovary syndrome after behavioural modification intervention-A randomized controlled trial. Clin Endocrinol (Oxf) 2019; 90: 468 - 478.

58. Dos Santos IK, Ashe MC, Cobucci RN, Soares GM, de Oliveira Maranhao TM, Dantas PMS. The effect of exercise as an intervention for women with polycystic ovary syndrome: A systematic review and meta-analysis. Medicine (Baltimore) 2020; 99: e19644.

59. Teede H, Tassone EC, Piltonen T, Malhotra J, Mol BW, 00000009.wmz A, Witchel SF, Joham A, McAllister V, Romualdi D, Thondan M, Costello M, Misso ML. Effect of the combined oral contraceptive pill and/or metformin in the management of polycystic ovary syndrome: A systematic review with meta-analyses. Clin Endocrinol (Oxf). 2019 Oct; 91(4): 479 - 489.

60. Wang QY, et al. Comparison of drospirenone-with cyproterone acetate-containing oral contraceptives, combined with metformin and lifestyle modifications in women with polycystic ovary syndrome and metabolic disorders: A prospective randomized control trial. Chinese medical journal. 2016; 129(8): 883 - 90.

61. Feng W, et al. Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin. Gynecological Endocrinology. 2016; 32(2): 147 - 50.

62. Shah A, Dodson WC, Kris-Etherton PM, et al. Effects of Oral Contraception and Lifestyle Modification on Incretins and 00000010.wmz Superfamily Hormones in PCOS. J Clin Endocrinol Metab. 2021 Jan 1; 106(1): 108 - 119.

63. Amiri M, Nahidi F, Yarandi RB, Khalili D, Tohidi M, Tehrani FR. Effects of oral contraceptives on the quality of life of women with polycystic ovary syndrome: a crossover randomized controlled trial. Health Qual Life Outcomes. 2020 Aug 31; 18(1): 293.

64. Fonseka S, Wijeyaratne CN, Gawarammana IB, Kalupahana NS, Rosairo S, Ratnatunga N, Kumarasiri R. Effectiveness of Low-dose Ethinylestradiol/Cyproterone Acetate and Ethinylestradiol/Desogestrel with and without Metformin on Hirsutism in Polycystic Ovary Syndrome: A Randomized, Double-blind, Triple-dummy Study. J Clin Aesthet Dermatol. 2020 Jul; 13(7): 18 - 23.

65. World Health Organization. 2015 Quick Reference Chart for the WHO Medical Eligibility Criteria for Contraceptive Use. Adapted from Medical Eligibility Criteria for Contraceptive Use, 5th Edition 2015; Available from: https://www.fhi360.org/sites/default/files/media/documents/chart-medical-eligibility-contraceptives-english.pdf.

66. Tay CT, Joham AE, Hiam DS, Gadalla MA, Pundir J, Thangaratinam S, Teede HJ, Moran LJ. Pharmacological and surgical treatment of nonreproductive outcomes in polycystic ovary syndrome: An overview of systematic reviews. Clin Endocrinol (Oxf). 2018; 89(5): 535 - 553.

67. Bayram N, van Wely M, Kaaijk EM, Bossuyt PM, van der Veen F. Using an electrocautery strategy or recombinant follicle stimulating hormone to induce ovulation in polycystic ovary syndrome: randomised controlled trial. BMJ. 2004 Jan 24; 328(7433): 192.

68. Fraison E, Kostova E, Moran LJ, Bilal S, Ee CC, Venetis C, Costello MF. Metformin versus the combined oral contraceptive pill for hirsutism, acne, and menstrual pattern in polycystic ovary syndrome. Cochrane Database Syst Rev. 2020 Aug 13; 8(8): CD005552.

69. Jensterle M, Kravos NA, Ferjan S, Goricar K, Dolzan V, Janez A. Long-term efficacy of metformin in overweight-obese PCOS: longitudinal follow-up of retrospective cohort. Endocr Connect. 2020; 9(1): 44 - 54.

70. Panda SR, Jain M, Jain S, Saxena R, Hota S. Effect of Orlistat Versus Metformin in Various Aspects of Polycystic Ovarian Syndrome: A Systematic Review of Randomized Control Trials. J Obstet Gynaecol India. 2018 Oct; 68(5): 336 - 343.

71. Abdalla MA, Deshmukh H, Atkin S, Sathyapalan T. A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome. TherAdvEndocrinolMetab. 2020; 11: 2042018820938305.

72. Showell MG, Mackenzie-Proctor R, Jordan V, Hodgson R, Farquhar C. Inositol for subfertile women with polycystic ovary syndrome. Cochrane Database Syst Rev 2018; 12: CD012378.

73. Wang R, Li W, Bordewijk EM, et al. First-line ovulation induction for polycystic ovary syndrome: an individual participant data meta-analysis. Hum Reprod Update 2019; 25: 717 - 732.

74. Morley LC, Tang T, Yasmin E, Norman RJ, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev. 2017; 11(11): CD003053.

75. Sharpe A, Morley LC, Tang T, Norman RJ, Balen AH. Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome. Cochrane Database Syst Rev 2019; 12: CD013505.

76. Wang R, Kim B, van Wely M et al. Treatment strategies for women with WHO group II anovulation: systematic review and network meta analysis. BMJ 2017; 356: j138.

77. Weiss NS, Kostova E, Nahuis M, Mol BWJ, van der Veen F, van Wely M. Gonadotrophins for ovulation induction in women with polycystic ovary syndrome. CochraneDatabaseSystRev. 2019 Jan 16; 1(1): CD010290.

78. Bordewijk EM, Ng KYB, Rakic L, et al. Laparoscopic ovarian drilling for ovulation induction in women with anovulatory polycystic ovary syndrome. Cochrane Database Syst Rev 2020; 2: CD001122.

79. Lepine S, Jo J, Metwally M, Cheong YC. Ovarian surgery for symptom relief in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2017; 11(11): CD009526.

80. Christ JP, Falcone T. Bariatric Surgery Improves Hyperandrogenism, Menstrual Irregularities, and Metabolic Dysfunction Among Women with Polycystic Ovary Syndrome (PCOS). Obes Surg. 2018 Aug; 28(8): 2171 - 2177.

81. Singh D, Arumalla K, Aggarwal S, Singla V, Ganie A, Malhotra N. Impact of Bariatric Surgery on Clinical, Biochemical, and Hormonal Parameters in Women with Polycystic Ovary Syndrome (PCOS). ObesSurg. 2020 Jun; 30(6): 2294 - 2300.

82. Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Hum Reprod. 2008; 23(3): 462 - 77.

83. Yaylal A, Bakacak M, Bakacak Z. The efficacy of different insulin-sensitizing agents on treatment outcomes in patients with polycystic ovary syndrome who underwent in-vitro fertilization: A retrospective, record-based, comparative study. J Gynecol Obstet Hum Reprod. 2020 Nov 23; 50(1): 102006.

84. Bordewijk E, Nahuis M, Costello M et al. Metformin during ovulation induction with gonadotrophins followed by timed intercourse or intrauterine insemination for subfertility associated with polycystic ovary syndrome. Cochrane Database Syst Rev 2017; 1: CD009090.

85. Tso LO, Costello MF, Albuquerque LET, Andriolo RB, Macedo CR. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2020 Dec 21; 12: CD006105.

86. Wu Y, Tu M, Huang Y, Liu Y, Zhang D. Association of Metformin With Pregnancy Outcomes in Women With Polycystic Ovarian Syndrome Undergoing In Vitro Fertilization: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020 Aug 3; 3(8): e2011995.

87. Bahri Khomami M, Joham AE, Boyle JA, Piltonen T, Arora C, Silagy M, Misso ML, Teede HJ, Moran LJ. The role of maternal obesity in infant outcomes in polycystic ovary syndrome-A systematic review, meta-analysis, and meta-regression. Obes Rev. 2019 Jun; 20(6): 842 - 858.

88. Bahri Khomami M, Joham AE, Boyle JA, Piltonen T, Silagy M, Arora C, Misso ML, Teede HJ, Moran LJ. Increased maternal pregnancy complications in polycystic ovary syndrome appear to be independent of obesity-A systematic review, meta-analysis, and meta-regression. Obes Rev. 2019 May; 20(5): 659 - 674.

89. Gunning MN, Sir Petermann T, Crisosto N, van Rijn BB, de Wilde MA, Christ JP, Uiterwaal CSPM, de Jager W, Eijkemans MJC, Kunselman AR, Legro RS, Fauser BCJM. Cardiometabolic health in offspring of women with PCOS compared to healthy controls: a systematic review and individual participant data meta-analysis. Hum Reprod Update. 2020 Jan 1; 26(1): 103 - 117.

90. Rodgers R, Avery J, Moore V, Davies M, Azziz R, Stener-Victorin E, Moran L, Robertson S, Stepto N, Norman R1, Teede HJ. Complex diseases and co-morbidities: polycystic ovary syndrome and type 2 diabetes mellitus. Endocr Connect. 2019 Feb 1. pii: EC-18-0502.R2. doi: 10.1530/EC-18-0502.

91. Horowitz E, Weissman A. The stair-step approach in treatment of anovulatory PCOS patients. Ther Adv Reprod Health. 2020 May 22; 14: 2633494120908818. doi: 10.1177/2633494120908818.

92. Gadalla MA, Norman RJ, Tay CT, Hiam DS, Melder A, Pundir J, Thangaratinam S, Teede HJ, Mol BWJ, Moran LJ. Medical and Surgical Treatment of Reproductive Outcomes in Polycystic Ovary Syndrome: An Overview of Systematic Reviews. Int J Fertil Steril. 2020 Jan; 13(4): 257 - 270. doi: 10.22074/ijfs.2020.5608.

93. Obeid R., 00000011.wmz C., Wilhelm M., Pietrzik K., Pilz S. Dietary and lifestyle predictors of folate insufficiency in non-supplemented German women. 1nt J Food Sci Nutr. 2018;

94. Oaly LE, Kirke PN, Molloy A, et al. Folate levels and neural tube defects. lmplications for prevention. JAMA 1995; 274(21): 1698 - 702.

95. Moreno L.A., Gottrand F., Huybrechts 1., Ruiz J.R., 00000012.wmz M., OeHenauw S.; HELENA Study Group. Nutrition and lifestyle in eu ropean adolescents: the HELENA (Healthy Lifestyle in Europe 00000013.wmz Nutrition in Adolescence) study. Adv Nutr. 2014 Sep; 5(5): 615S - 623S.

96. Osterhues A, Holzgreve W and Michels KB. Shall we put the world on folate? Lancet 2009; 374(9694): 959 - 61

97. Escobar-Morreale HF, 00000014.wmz M, 00000015.wmz F. Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. Fertil Steril. 2011 Mar 1; 95(3): 1048 - 58. e1 - 2.

98. Carvalho MJ, Subtil S, Rodrigues 00000016.wmz, Oliveira J, Figueiredo-Dias M. Controversial association between polycystic ovary syndrome and breast cancer. Eur J Obstet Gynecol Reprod Biol. 2019 Dec; 243: 125 - 132. doi: 10.1016/j.ejogrb.2019.10.011.

99. Meczekalski B, 00000017.wmz GR, 00000018.wmz MT, Chedraui P, 00000019.wmz FR. The polycystic ovary syndrome and gynecological cancer risk. Gynecol Endocrinol. 2020 Apr; 36(4): 289 - 293. doi: 10.1080/09513590.2020.1730794.

100. Wen Y, Wu X, Peng H, Li C, Jiang Y, Su Z, Liang H, Liu J, He J, Liang W. Breast cancer risk in patients with polycystic ovary syndrome: a Mendelian randomization analysis. Breast Cancer Res Treat. 2021 Feb; 185(3): 799 - 806. doi: 10.1007/s10549-020-05973-z.

101. Беленькая Лилия Васильевна Критерии ожирения в азиатской популяции. Обзор литературы//Acta Biomedica Scientifica. 2018. N 3, 99 - 102

102. 00000020.wmz AS, Witchel SF, Hoeger KM, Oberfield SE, Vogiatzi MG, Misso M, Garad R, Dabadghao P, Teede H. Adolescent polycystic ovary syndrome according to the international evidence-based guideline. BMC Med. 2020 Mar 24; 18(1): 72. doi: 10.1186/s12916-020-01516-x. PMID: 32204714; PMCID: PMC7092491.

103. Aversa A, La Vignera S, Rago R,Gambineri A, Nappi RE, Calogero AE and Ferlin A (2020) Fundamental Concepts and Novel Aspects of Polycystic Ovarian Syndrome: Expert Consensus Resolutions.Front. Endocrinol. 11: 516. Doi: 10.3389/fendo.2020.00516

104. Kazerooni T, Asadi N, Dehbashi S, Zolghadri J. Effect of folic acid in women with and without insulin resistance who have hyperhomocysteinemic polycystic ovary syndrome. Int J Gynaecol Obstet. 2008 May; 101(2): 156 - 60. Doi: 10.1016/j.ijgo.2007.10.024.

105. Mondal K, Chakraborty P, Kabir SN. Hyperhomocysteinemia and hyperandrogenemia share PCSK9-LDLR pathway to disrupt lipid homeostasis in PCOS. Res Commun. 2018 Apr 13. pii: S0006 - 291 X (18) 30847-7

106. Escobar-Morreale HF Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018 May; 14(5): 270 - 284.

107. Glintborg D, Rubin KH, Nybo M, Abrahamsen B, Andersen M. Cardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome. Cardiovasc Diabetol. 2018 Mar 8; 17(1): 37.

108. Farquhar C, Brown J, Marjoribanks J. Laparoscopic drilling by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. Cochrane Database Syst Rev. 2012 Jun 13; 6: CD001122.

109. Lim S. S. et al. The effect of obesity on polycystic ovary syndrome: a systematic review and meta analysis//Obesity Reviews. - 2013. - Т. 14. - N. 2. - С. 95 - 109

110. Wild S. et al. Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study//Human Fertility. - 2000. - Т. 3. - N. 2. - С. 101 - 105.

111. van Zuuren E. J. et al. Interventions for hirsutism (excluding laser and photoepilation therapy alone)//Cochrane database of systematic reviews. - 2015. - N. 4.

112. Hashim H. A., Foda O., El Rakhawy M. Unilateral or bilateral laparoscopic ovarian drilling in polycystic ovary syndrome: a meta-analysis of randomized trials//Archives of gynecology and obstetrics. - 2018. - Т. 297. - N. 4. - С. 859 - 870.

113. Mulder C. L. et al. Cardio metabolic risk factors among young infertile women: a systematic review and meta analysis//BJOG: An International Journal of Obstetrics & Gynaecology. - 2020. - Т. 127. - N. 8. - С. 930 - 939.

114. Kahal H. et al. The prevalence of obstructive sleep apnoea in women with polycystic ovary syndrome: a systematic review and meta-analysis//Sleep and Breathing. - 2020. - Т. 24. - N. 1. - С. 339 - 350.

115. Oriolo C. et al. Steroid biomarkers for identifying non-classic adrenal hyperplasia due to 21-hydroxylase deficiency in a population of PCOS with suspicious levels of 17OH-progesterone//Journal of endocrinological investigation. - 2020. - Т. 43. - N. 10. - С. 1499 - 1509.

116. Jonard S., Robert Y., Dewailly D. Revisiting the ovarian volume as a diagnostic criterion for polycystic ovaries//Human reproduction. - 2005. - Т. 20. - N. 10. - С. 2893 - 2898.

117. Pinola P. et al. 00000021.wmz hormone: correlation with testosterone and oligo-or amenorrhoea in female adolescence in a population-based cohort study//Human Reproduction. - 2014. - Т. 29. - N. 10. - С. 2317 - 2325.

118. Moran L. J. et al. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis//Human reproduction update. - 2010. - Т. 16. - N. 4. - С. 347 - 363.

119. Tosi F. et al. Implications of androgen assay accuracy in the phenotyping of women with polycystic ovary syndrome//The Journal of Clinical Endocrinology & Metabolism. - 2016. - Т. 101. - N. 2. - С. 610 - 618.

120. Steck T., Wernze H. Is determination of the "free androgen index" for hormone screening in polycystic ovaries of value?//Gynakologisch-geburtshilfliche Rundschau. - 1993. - Т. 33. - N. 3. - С. 173 - 179.

121. Kollmann M. et al. Strategies for improving outcome of assisted reproduction in women with polycystic ovary syndrome: systematic review and meta analysis//Ultrasound in Obstetrics & Gynecology. - 2016. - Т. 48. - N. 6. - С. 709 - 718.

122. Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, Bowe WP, Graber EM, Harper JC, Kang S, Keri JE, Leyden JJ, Reynolds RV, Silverberg NB, Stein Gold LF, Tollefson MM, Weiss JS, Dolan NC, Sagan AA, Stern M, Boyer KM, Bhushan R. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016 May; 74(5): 945 - 73.e33. doi: 10.1016/j.jaad.2015.12.037. Epub 2016 Feb 17. Erratum in: J Am Acad Dermatol. 2020 Jun; 82(6): 1576.

123. Barrionuevo P, Nabhan M, Altayar O, Wang Z, Erwin PJ, Asi N, Martin KA, Murad MH. Treatment Options for Hirsutism: A Systematic Review and Network Meta-Analysis. J Clin Endocrinol Metab. 2018 Apr 1; 103(4): 1258 - 1264.

124. Derewianka-Polak M. et al. Polycystic ovary syndrome and mental disorders-discussion on the recommendations of the European Society of Human Reproduction and Embryology (ESHRE)//Current Problems of Psychiatry. - 2019. - Т. 20. - N. 4

125. Zeinalzadeh M., Basirat Z., Esmailpour M. Efficacy of letrozole in ovulation induction compared to that of clomiphene citrate in patients with polycystic ovarian syndrome//The Journal of reproductive medicine. - 2010. - Т. 55. - N. 1 - 2. - С. 36 - 40

126. Franik, S., Eltrop, S. M., Kremer, J. A., Kiesel, L., & Farquhar, C. (2018). Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews. doi: 10.1002/14651858.cd010287.pub3